Welcome to our dedicated page for Longeveron SEC filings (Ticker: LGVN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to Longeveron Inc. (NASDAQ: LGVN) SEC filings, giving investors a primary source of regulatory information about the clinical stage biotechnology company and its cellular therapy programs. Longeveron files a range of documents with the U.S. Securities and Exchange Commission, including Forms 8-K, registration statements, and other reports that describe its business, capital structure, and material events.
Recent 8-K filings have detailed topics such as public offerings of Class A common stock and warrants, an at-the-market (ATM) offering agreement, financial results for quarterly periods, changes in executive leadership and board composition, and a Nasdaq notice regarding the minimum bid price requirement for continued listing on The Nasdaq Capital Market. These filings also discuss how the company intends to use offering proceeds, including funding clinical and regulatory development of its lead mesenchymal stem cell therapy, laromestrocel (Lomecel-B), for indications like hypoplastic left heart syndrome (HLHS), Alzheimer’s disease, and pediatric dilated cardiomyopathy.
Through registration statements on Form S-1 and related amendments, Longeveron outlines the terms of securities offerings, its status as an emerging growth and smaller reporting company, and risk factors associated with its business and development plans. Investors can also review disclosures about ATM programs and material definitive agreements with placement agents.
On Stock Titan, these LGVN SEC filings are paired with AI-powered summaries that highlight key points, such as financing terms, listing compliance updates, and planned uses of capital. Users can quickly locate quarterly and annual reporting documents, transaction-related filings, and other regulatory disclosures to better understand Longeveron’s operations, funding strategy, and clinical development priorities.
Longeveron Inc. is a clinical-stage biotech focused on regenerative cell therapies built around its lead product, laromestrocel (Lomecel‑B), an allogeneic bone‑marrow–derived mesenchymal stem cell therapy. The company is developing laromestrocel for four indications: Hypoplastic Left Heart Syndrome (HLHS), mild Alzheimer’s disease, pediatric dilated cardiomyopathy, and aging‑related frailty.
For HLHS, laromestrocel has Rare Pediatric Disease, Orphan Drug, and Fast Track designations, and the pivotal Phase 2b ELPIS II trial is fully enrolled with top‑line data expected in the third quarter of 2026. For mild Alzheimer’s, a Phase 2a trial (CLEAR MIND) showed a favorable safety profile and signals of efficacy, leading to RMAT and Fast Track designations and FDA alignment on a planned pivotal seamless Phase 2/3 design, with the possibility of a BLA based on positive interim data.
The company operates a cGMP facility in Miami for early‑phase supply but plans to use a contract development and manufacturing organization for potential commercial production, and it has built an extensive global patent and trademark portfolio around laromestrocel and its manufacturing and potency assays.
Longeveron Inc. reported that Chief Executive Officer Willard Stephen H received several equity awards. He was granted a stock option for 200,000 shares of Class A common stock at an exercise price of
He also received an initial hire award of 200,000 shares of Class A common stock, with 105,533 of those shares withheld to cover tax obligations. In addition, he was granted 200,000 time-based vesting RSUs. Following these awards and tax withholding, he directly holds 294,467 shares of Class A common stock, which includes RSUs subject to future vesting.
Longeveron Inc. Chief Executive Officer Willard Stephen H filed an initial ownership report on Class A Common Stock. The Form 3 shows he beneficially owns no securities, with total Class A Common Stock reported as zero. A footnote explicitly states that no securities are beneficially owned, establishing a baseline of zero ownership for future insider filings.
Longeveron Inc. completed an initial closing of a private placement, raising aggregate gross proceeds of approximately
The agreement also provides for a potential second closing for additional gross proceeds of about
Longeveron Inc. reported that it temporarily fell out of compliance with a Nasdaq listing rule after the resignation of director Richard Kender, who also served as audit committee chair and audit committee financial expert.
Kender resigned from the Board and Audit Committee effective March 3, 2026, citing his changing role at Seres Therapeutics, where he had just been named Executive Chairman and Interim CEO. The company states his resignation was not due to any disagreement regarding Longeveron’s operations, policies, practices, management, or Board.
On March 4, 2026, the Board appointed existing director Dr. Roger Hajjar to the Audit Committee, restoring the required three independent members. The company plans to add at least one director who will qualify as both independent and an audit committee financial expert by the earlier of the next annual shareholders meeting or within the 180‑day cure period allowed under Nasdaq Listing Rule 5605(c)(4).
Longeveron Inc. is asking shareholders to approve an amendment to its Certificate of Incorporation to permit a board‑authorized reverse stock split of its Class A and Class B common stock at a ratio between 1:5 and 1:20. The Board may elect the exact ratio within that range and whether or when to file the amendment if stockholders approve the proposal.
The stated purpose is to raise the per‑share trading price of Class A common stock to satisfy Nasdaq’s minimum bid price requirement of $1.00 and to aid potential capital‑raising efforts. The Board recommends a vote FOR the Reverse Stock Split Proposal and an adjournment proposal to permit additional solicitation if needed. The Record Date for voting is March 9, 2026, and the Board’s authority to effect the split terminates if not implemented prior to December 31, 2026.
Longeveron Inc. appointed industry veteran Stephen H. Willard as permanent Chief Executive Officer, effective February 11, 2026, succeeding interim CEO Than Powell, who will remain in a business development role. Willard brings more than 30 years of pharma and biotech leadership experience, including multiple prior CEO positions.
Under a new letter agreement, Willard’s base salary is set at $500,000 per year, but roughly 50% will be temporarily deferred, alongside a similar deferral by Executive Chairman Dr. Joshua Hare, to support the company’s financial needs. During this deferral period, Willard will receive $250,000 per year, payable in cash or equity at the company’s discretion.
Willard is also slated to receive an initial equity package consisting of 200,000 shares of Class A common stock, 200,000 RSUs, and stock options for 200,000 shares, with equity vesting quarterly over four years. Separately, as part of broader cost-cutting tied to cash runway review, Longeveron is implementing a temporary 50% compensation reduction for its CEO and Executive Chairman, employee furloughs, reduced board fees, and travel limits, and plans to grant each affected executive 50,000 RSUs vesting around June 1, 2026.
Lincoln Alternative Strategies LLC reports that it no longer beneficially owns any shares of Longeveron Inc. common stock. The filing shows 0 shares beneficially owned, representing 0% of the class, with no sole or shared voting or dispositive power.
The filer confirms it owns 5 percent or less of Longeveron’s common stock and states that the securities referenced were not acquired or held for the purpose of changing or influencing control of the company.
Longeveron Inc. Chief Medical Officer Nataliya Agafonova reported a Form 4 transaction involving company Class A common stock. On 01/02/2026, 10,250 shares were withheld at a price of $0.593 per share, identified with transaction code "F," which the footnotes explain were shares withheld to satisfy tax obligations arising from the vesting of a restricted stock unit (RSU) award. Following this tax withholding, she beneficially owned 216,564 shares in total, which the disclosure notes includes RSUs that are still subject to future vesting.
Longeveron Inc. officer reports routine tax withholding transaction. General Counsel and Secretary Paul T. Lehr filed a Form 4 for a transaction on 01/02/2026 involving Class A Common Stock of Longeveron Inc. (LGVN).
The filing shows that 6,952 shares were withheld at a price of $0.593 per share to satisfy tax obligations tied to the vesting of a restricted stock unit (RSU) award. Following this tax withholding, Lehr beneficially owned 344,177 shares, which include RSUs that are subject to future vesting. This reflects an administrative equity compensation event rather than an open-market purchase or sale.